Wide Ranks

KYMR

Kymera Therapeutics, Inc.

46.86

Top Statistics
Market Cap 3 B Forward PE -14.05 Revenue Growth -20.90 %
Current Ratio 8.55 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -191.26 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -13.51 Enterprise / Revenue 29.39 Price To Sales Trailing12 Months 34.66
Profitability
Profit Margins -191.26 % Operating Margins -1927.93 %
Balance Sheet
Total Cash 549 M Total Cash Per Share 8.49 Total Debt 88 M
Total Debt To Equity 9.88 Current Ratio 8.55 Book Value Per Share 13.79
All Measures
Short Ratio 2284.00 % Message Board Id finmb_542085131 Shares Short Prior Month 9 M
Return On Equity -0.2600 City Watertown Uuid fe087242-38df-325c-aac8-26165faa63ce
Previous Close 45.98 First Trade Date Epoch Utc 1 B Book Value 13.79
Beta 2.22 Total Debt 88 M Volume 388100
Price To Book 3.40 Fifty Two Week Low 19.73 Total Cash Per Share 8.49
Total Revenue 87 M Shares Short Previous Month Date 1 B Target Median Price 56.00
Max Age 86400 Recommendation Mean 1.61 Sand P52 Week Change 0.3133
Operating Margins -1927.93 % Target Mean Price 57.76 Net Income To Common -167474000
Short Percent Of Float 0.1573 Implied Shares Outstanding 64 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 538030 Average Volume10days 538030
Total Cash 549 M Next Fiscal Year End 1 B Revenue Per Share 1.26
Held Percent Insiders 0.0127 Ebitda Margins -217.55 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 45.98
Target Low Price 38.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 46.91
Open 46.05 Free Cashflow -94098128 State MA
Dividend Yield 0.00 % Return On Assets -0.1538 Time Zone Short Name EST
Trailing Eps -2.34 Day Low 46.05 Address1 200 Arsenal Yards Boulevard
Shares Outstanding 64 M Price Hint 2 Target High Price 90.00
Website https://www.kymeratx.com 52 Week Change 1.26 Average Volume 422320
Forward Eps -3.11 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 828.60 % Is_sp_500 False Regular Market Day High 47.73
Profit Margins -191.26 % Debt To Equity 9.88 Fifty Two Week High 53.27
Day High 47.73 Shares Short 9 M Regular Market Open 46.05
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 29.39
Revenue Growth -20.90 % Shares Percent Shares Out 0.1409 Operating Cashflow -124672000
Currency USD Time Zone Full Name America/New_York Market Cap 3 B
Is_nasdaq_100 False Zip 02472 Quote Type EQUITY
Industry Biotechnology Long Name Kymera Therapeutics, Inc. Regular Market Day Low 46.05
Held Percent Institutions 1.08 Current Price 46.86 Address2 Suite 230
Enterprise To Ebitda -13.51 Financial Currency USD Current Ratio 8.55
Gross Margins -152.85 % Industry Disp Biotechnology Number Of Analyst Opinions 17
Country United States Float Shares 43 M Two Hundred Day Average 41.11
Enterprise Value 2 B Price To Sales Trailing12 Months 34.66 Forward PE -14.05
Regular Market Volume 388100 Ebitda -190490000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.

It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.

The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.